Better Therapeutics (acquired by Click Therapeutics)

Better Therapeutics is a prescription digital therapeutics (PDT) company that develops software-based solutions to address cardiometabolic diseases. The company's flagship product, AspyreRx, received FDA authorization in July 2023 as the first prescription-only digital therapeutic for treating adults with type two diabetes. AspyreRx delivers cognitive behavioral therapy (CBT) through a smartphone application, aiming to target the underlying psychological, behavioral, and cognitive factors that contribute to type two diabetes. The therapy is designed to enable changes in neural pathways, facilitating lasting behavioral changes in patients.

The company's proprietary platform focuses on developing FDA-regulated digital therapeutics for conditions such as type two diabetes, heart disease, and other cardiometabolic diseases. Better Therapeutics' approach is based on the premise that addressing the root causes of these diseases can potentially improve patient health while reducing healthcare costs. In clinical trials, the company's digital therapeutic demonstrated statistically significant improvements in A1c levels, a key measure of blood sugar control in diabetes patients. The primary endpoint results from a pivotal trial showed a clinically meaningful difference of -0.4% in A1c between the intervention and control groups.

Better Therapeutics launched AspyreRx commercially in October 2023, following its FDA authorization. The company is actively engaging with health plans, Pharmacy Benefit Managers (PBMs), and Group Purchasing Organizations (GPOs) to secure broad coverage for AspyreRx. In January 2024, Better Therapeutics entered into a rebate agreement with one of the largest PBMs in the US, covering over 70 million lives and potentially increasing accessibility to AspyreRx for patients with type two diabetes.